DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Kim SY, Kim SM, Chang HJ. et al.
SoLAT (Sorafenib Lenvatinib alternating treatment): A new treatment protocol
with alternating sorafenib and lenvatinib for refractory thyroid cancer.
BMC Cancer 2018;
18: 956
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.